Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYB | P10242 | 14/20 | 0.62 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.57 |
| ▸ | TUBB | P07437 | 3/20 | 0.57 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.57 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.57 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.57 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.57 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.57 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.57 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.57 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.57 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.57 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.57 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.57 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.57 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5048596 | 0.90 | MYB (0.62) | MYBKDM4EMEN1MAPTKMT2A | |
| SCHEMBL4331540 | 0.84 | MYB (0.87) | MYBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4543107 | 0.83 | MYB (0.58) | MYBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4537499 | 0.83 | MYB (0.57) | MYBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4537843 | 0.82 | TUBB4A (0.68) | MYBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4252566 | 0.80 | POLB (0.55) | MYBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4537606 | 0.80 | TUBB4A (0.71) | MYBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4560656 | 0.80 | MYB (0.58) | MYBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL19732221 | 0.79 | TUBB4A (0.70) | MYBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4539906 | 0.79 | TUBB4A (0.65) | MYBTUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638025-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2020-02-05 | — | — | EP | disclosed |
| EP-2638025-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2020-02-05 | — | — | EP | disclosed |
| US-20180334442-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | Ruprecht-Karls-Universität Heidelberg (DE) | 2018-11-22 | — | — | US | disclosed |
| US-10065939-B2 | Chromene derivatives and their analogs as Wnt pathway antagonists | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2018-09-04 | — | — | US | disclosed |
| EP-2638026-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2018-07-11 | — | — | EP | disclosed |
| EP-2638026-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2018-07-11 | — | — | EP | disclosed |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-12-08 | — | — | US | disclosed |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-12-08 | — | — | US | disclosed |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-12-08 | — | — | US | disclosed |
| US-9371333-B2 | Chromene derivatives and their analoga as Wnt pathway antagonists | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-06-21 | — | — | US | disclosed |
| US-20130303550-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303550-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303550-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-07 | — | — | US | disclosed |
| EP-2638026-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | Deutsches Krebsforschungszentrum (DKFZ) (DE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2638025-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | Deutsches Krebsforschungszentrum (DKFZ) (DE) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062905-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062901-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303550-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | MYB 142/4885TUBB4A 2905/4885TUBB 3789/4885 |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | MYB 152/4885TUBB4A 3213/4885TUBB 3786/4885 |
| US-10065939-B2 | Chromene derivatives and their analogs as Wnt pathway antagonists | WNT3, WNT1, WNT3A | MYB 152/4885TUBB4A 3213/4885TUBB 3786/4885 |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | MYB 172/4885TUBB4A 3809/4885TUBB 4669/4885 |
| US-20180334442-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | MYB 152/4885TUBB4A 3213/4885TUBB 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.